Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti‐seizure medication: Levetiracetam case study

Levetiracetam (LEV), a well‐established anti‐seizure medication (ASM), was launched before the original ICH S7B nonclinical guidance assessing QT prolongation potential and the introduction of the Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm. No information was available on its effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Delaunois, Annie, Mathy, François‐Xavier, Cornet, Miranda, Gryshkova, Vitalina, Korlowski, Chloé, Bonfitto, François, Koch, Juliane, Schlit, Anne‐Françoise, Hebeisen, Simon, Passini, Elisa, Rodriguez, Blanca, Valentin, Jean‐Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903303/
https://www.ncbi.nlm.nih.gov/pubmed/36748725
http://dx.doi.org/10.1002/prp2.1059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903303/
https://www.ncbi.nlm.nih.gov/pubmed/36748725
http://dx.doi.org/10.1002/prp2.1059

Ejemplares similares